| __timestamp | Neurocrine Biosciences, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 382096000000 |
| Thursday, January 1, 2015 | 81491000 | 345927000000 |
| Friday, January 1, 2016 | 94291000 | 312303000000 |
| Sunday, January 1, 2017 | 121827000 | 325441000000 |
| Monday, January 1, 2018 | 160524000 | 368298000000 |
| Tuesday, January 1, 2019 | 200000000 | 492381000000 |
| Wednesday, January 1, 2020 | 275000000 | 455833000000 |
| Friday, January 1, 2021 | 328100000 | 526087000000 |
| Saturday, January 1, 2022 | 463800000 | 633325000000 |
| Sunday, January 1, 2023 | 565000000 | 729924000000 |
| Monday, January 1, 2024 | 731100000 | 729924000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, research and development (R&D) investments are pivotal for innovation and growth. Over the past decade, Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. have demonstrated contrasting R&D strategies. Takeda, a global leader, has consistently invested heavily, with expenditures peaking at approximately 730 billion yen in 2023, marking a 91% increase since 2014. In contrast, Neurocrine, a dynamic biotech firm, has shown a remarkable growth trajectory, with R&D spending surging by over 1,100% from 2014 to 2023, reaching around 565 million dollars. This stark difference highlights Takeda's established market presence and Neurocrine's aggressive expansion strategy. Notably, 2024 data for Neurocrine is unavailable, indicating potential shifts or reporting delays. As these companies continue to innovate, their R&D investments will be crucial in shaping the future of healthcare.
Explore how two giants fuel innovation through strategic R&D investments.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Takeda Pharmaceutical Company Limited vs Amicus Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or Bausch Health Companies Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Soleno Therapeutics, Inc.
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Travere Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: Neurocrine Biosciences, Inc. vs Madrigal Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Neurocrine Biosciences, Inc. vs PTC Therapeutics, Inc.
Neurocrine Biosciences, Inc. or MannKind Corporation: Who Invests More in Innovation?